Breaking News, Collaborations & Alliances

GSK, Dyanavax in Inflammation Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Dynavax Technologies have entered a worldwide strategic alliance to discover, develop and commercialize novel inhibitors of endosomal Toll-like Receptors (TLRs) for the treatment of immuno-inflammatory diseases. Dynavax will receive an initial payment of $10 million and GSK will receive an exclusive option over four programs targeting autoimmune and inflammatory diseases such as lupus, psoriasis, and rheumatoid arthritis. Dynavax’s lead inhibitor drug candidate, DV1079, i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters